Translation matters: Protein synthesis defects in inherited disease

Nature Reviews Genetics

Volumn 8, Issue 9, 2007, Pages 711-723

  Scheper, Gert C ^a   Van Der Knaap, Marjo S ^a   Proud, Christopher G ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; ELONGATION FACTOR; MESSENGER RNA; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL RNA; RIBOSOME RNA; TRANSFER RNA;

CYTOSOL; GENE CONTROL; GENE MUTATION; GENETIC DISORDER; GENETIC HETEROGENEITY; HERITABILITY; HUMAN; MITOCHONDRION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATOR GENE; REVIEW; RIBOSOME; RNA TRANSLATION; TRANSLATION INITIATION;

5' UNTRANSLATED REGIONS; ANIMALS; GENE EXPRESSION REGULATION; GENETIC DISEASES, INBORN; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; MUTATION; PEPTIDE ELONGATION FACTORS; PEPTIDE INITIATION FACTORS; PEPTIDE TERMINATION FACTORS; PROTEIN BIOSYNTHESIS; RIBOSOMES; RNA, TRANSFER;

EID: 34548052424     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg2142     Document Type: Review

References (117)

1. Jackson, R. J. Alternative mechanisms of initiating translation of mammalian mRNAs. Biochem. Soc. Trans. 33, 1231-1241 (2005).
2. Mangus, D. A., Evans, M. C. & Jacobson, A. Poly(A)-binding proteins: multifunctional scaffolds for the post-transcriptional control of gene expression. Genome Biol. 4, 223 (2003).
3. de Moor, C. H., Meijer, H. & Lissenden, S. Mechanisms of translational control by the 3′ UTR in development and differentiation. Semin. Cell Dev. Biol. 16, 49-58 (2005).
4. Cazzola, M. & Skoda, R. C. Translational pathophysiology: a novel molecular mechanism of human disease. Blood 95, 3280-3288 (2000).
5. Kozak, M. Emerging links between initiation of translation and human diseases. Mamm. Genome 13, 401-410 (2002).
6. Pickering, B. M. & Willis, A. E. The implications of structured 5′ untranslated regions on translation and disease. Semin. Cell Dev. Biol. 16, 39-47 (2005).
7. Stoneley, M. et al. c-Myc protein synthesis is initiated from the internal ribosome entry segment during apoptosis. Mol. Cell. Biol. 20, 1162-1169 (2000).
8. Stoneley, M., Paulin, F. E. M., Le Quesne, J. P. C., Chappell, S. A. & Willis, A. E. c-myc 5′ untranslated region contains an internal ribosome entry segment. Oncogene 16, 423-428 (1998).
9. Paulin, F. E. M., Chappell, S. A. & Willis, A. E. A single nucleotide change in the c-myc internal ribosome entry segment leads to enhanced binding of a group of protein factors. Nucl. Acids Res. 26, 3097-3103 (1998).
10. Evans, J. R. et al. Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo. Oncogene 22, 8012-8020 (2003).
11. Hudder, A. & Werner, R. Analysis of a Charcot-Marie-Tooth disease mutation reveals an essential internal ribosome entry site element in the connexin-32 gene. J. Biol. Chem. 275, 34586-34591 (2000).
12. Yoon, A. et al. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 312, 902-906 (2006). A mouse model for X-linked dyskeratosis congenita shows a defect in IRES-mediated translation initiation. Together with reference 14, this paper outlines the discussion about the role of translation in this disease.
13. Liu, J. M. & Ellis, S. R. Ribosomes and marrow failure: coincidental association or molecular paradigm? Blood 107, 4583-4588 (2006).
14. Wong, J. M. & Collins, K. Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes Dev. 20, 2848-2858 (2006). This paper shows that telomere defects are the primary cause of X-linked dyskeratosis congenita in patients' cells, while normal levels of rRNA pseudouridine modification and normal kinetics of rRNA precursor processing were observed.
15. Dokal, I. Severe aplastic anemia including Fanconi's anemia and dyskeratosis congenita. Curr. Opin. Hematol. 3, 453-460 (1996).
16. Vulliamy, T. & Dokal, I. Dyskeratosis congenita. Semin. Hematol. 43, 157-166 (2006).
17. Liu, L. et al. Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma. Nature Genet. 21, 128-132 (1999).
18. Choi, B. Y. et al. The tumor suppressor p16(INK4a) prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity. Nature Struct. Mol. Biol. 12, 699-707 (2005).
19. Hinnebusch, A. G. in Translational Control of Gene Expression (eds Sonenberg, N., Hershey, J. W. B. & Mathews, M. B.) 185-243 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2000).
20. Proud, C. G. eIF2 and the control of cell physiology. Semin. Cell Dev. Biol. 16, 3-12 (2005).
21. Van der Knaap, M. S. et al. Mutations of each of the five subunits of translation initiation factor eIF2B can cause leukoencephalopathy with vanishing white matter. Ann. Neurol. 51, 264-270 (2002). eIF2B is the first cytosolic translation initiation factor to be identified as being related to human disease. Despite it essential role in protein synthesis, mutations lead to a severe childhood white matter disorder.
22. Fogli, A. et al. A severe variant of childhood ataxia with central hypomyelination/vanishing white matter leukoencephalopathy related to eIF21B5 mutation. Neurology 59, 1966-1968 (2002).
23. Van der Knaap, M. S. et al. eIF2B-related disorders: antenatal onset and involvement of multiple organs. Am. J. Hum. Genet. 73, 1199-1207 (2003).
24. Fogli, A. et al. The effect of genotype on the natural history of eIF2B-related leukodystrophies. Neurology 62, 1509-1517 (2004).
25. Van der Knaap, M. S. et al. Arg113His mutation in eIF2Bepsilon as cause of leukoencephalopathy in adults. Neurology 62, 1598-1600 (2004).
26. Prass, K. et al. Adult-onset leukoencephalopathy with vanishing white matter presenting with dementia. Ann. Neurol. 50, 665-668 (2001).
27. Fogli, A. et al. Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patients. Eur. J. Hum. Genet. 12, 561-566 (2004).
28. van Kollenburg. B. et al. Regulation of protein synthesis in lymphoblasts from vanishing white matter patients. Neurobiol. Dis. 21, 496-504 (2006).
29. Kantor, L. et al. Heightened stress response in primary fibroblasts expressing mutant eIF2B genes from CACH/VWM leukodystrophy patients. Hum. Genet. 118, 99-106 (2005).
30. Van der Voorn, J. P. et al. The unfolded protein response in vanishing white matter disease. J. Neuropathol. Exp. Neurol. 64, 770-775 (2005).
31. van Kollenburg, B. et al. Glia-specific activation of all pathways of the unfolded protein response in vanishing white matter disease. J. Neuropathol. Exp. Neurol. 65, 707-715 (2006).
32. McCullough, K. D., Martindale, J. L., Klotz, L. O., Aw, T. Y. & Holbrook, N. J. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating BCL2 and perturbing the cellular redox state. Mol. Cell. Biol. 21, 1249-1259 (2001).
33. Scheper, G. C., Proud, C. G. & Van der Knaap, M. S. Defective translation initiation causes vanishing of cerebral white matter. Trends Mol. Med. 12, 159-166 (2006).
34. Schiffmann, R. & Elroy-Stein, O. Childhood ataxia with CNS hypomyelination/vanishing white matter disease - a common leukodystrophy caused by abnormal control of protein synthesis. Mol. Genet. Metab. 88, 7-15 (2006).
35. Senee, V. et al. Wolcott-Rallison syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity. Diabetes 53, 1876-1883 (2004).
36. Scheuner, D. et al. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol. Cell 7, 1165-1176 (2001).
37. Zhang, P. et al. The PERK eukaryotic initiation factor 2α kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. Mol. Cell. Biol. 22, 3864-3874 (2002).
38. Zhang, W. et al. PERK EIF2AK3 control of pancreatic β cell differentiation and proliferation is required for postnatal glucose homeostasis. Cell Metab. 4, 491-497 (2006). This paper shows that PERK is specifically required in the insulin-secreting β-cells during the fetal and early neonatal period, and not during adult stages, for postnatal glucose homeostasis.
39. Chambers, D. M., Peters, J. & Abbott, C. M. The lethal mutation of the mouse wasted (wst) is a deletion that abolishes expression of a tissue-specific isoform of translation elongation factor 1α, encoded by the Eef1a2 gene. Proc. Natl Acad. Sci. USA 95, 4463-4468 (1998).
40. Khalyfa, A. et al. Characterization of elongation factor-1A (eEF1A-1) and eEF1A-2/S1 protein expression in normal and wasted mice. J. Biol. Chem. 276, 22915-22922 (2001).
41. Chang, R. & Wang, E. Mouse translation elongation factor eEF1A-2 interacts with Prdx-I to protect cells against apoptotic death induced by oxidative stress. J. Cell Biochem. 100, 267-278 (2007).
42. Brito, M. et al. Polyglycine expansions in eRF3/GSPT1 are associated with gastric cancer susceptibility. Carcinogenesis 26, 2046-2049 (2005).
43. Malta-Vacas, J. et al. Differential expression of the eukaryotic release factor 3 (eRF3/GSPT1) according to gastric cancer histological types. J. Clin. Pathol. 58, 621-625 (2005).
44. Kerem, E. Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr. Opin. Pulm. Med. 10, 547-552 (2004).
45. Welch, E. M. et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87-91 (2007). The development of PTC124 as a possible treatment for diseases caused by nonsense mutations shows the important benefits of fundamental research on protein synthesis.
46. Draptchinskaia, N. et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nature Genet. 21, 169-175 (1999).
47. Gazda, H. T. et al. Defective ribosomal protein gene expression alters transcription, translation, apoptosis, and oncogenic pathways in Diamond-Blackfan anemia. Stem Cells 24, 2034-2044 (2006).
48. Flygare, J. et al. Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits. Blood 109, 980-986 (2007).
49. Choesmel, V. et al. Impaired ribosome biogenesis in Diamond-Blackfan anemia. Blood 109, 1275-1283 (2007).
50. Koga, Y., Ohga, S., Nomura, A., Takada, H. & Hara, T. Reduced gene expression of clustered ribosomal proteins in Diamond-Blackfan anemia patients without RPS19 gene mutations. J. Pediatr. Hematol. Oncol. 28, 355-361 (2006).
51. Bommer, U. A., Stahl, J., Henske, A., Lutsch, G. & Bielka, H. Identification of proteins of the 40S ribosomal subunit involved in interaction with initiation factor eIF-2 in the quaternary initiation complex by means of monospecific antibodies. FEBS Lett. 233, 114-118 (1988).
52. Menne, T. F. et al. The Shwachman-Bodian-Diamond syndrome protein mediates translational activation of ribosomes in yeast. Nature Genet. 39, 486-495 (2007).
53. Thiel, C. T. et al. Severely incapacitating mutations in patients with extreme short stature identify RNA-processing endoribonuclease RMRP as an essential cell growth regulator. Am. J. Hum. Genet. 77, 795-806 (2005).
54. Vulliamy, T. et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 413, 432-435 (2001).
55. Walne, A. J. et al. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum. Mol. Genet. 16, 1619-1629 (2007).
56. Morimoto, K., Lin, S. & Sakamoto, K. The functions of RPS19 and their relationship to Diamond-Blackfan anemia: a review. Mol. Genet. Metab. 90, 538-562 (2006). A review describing the functions of RPS19, the first ribosomal protein to be found to be related to human disease.
57. 't Hart, L. M. et al. Evidence that the mitochondrial leucyl tRNA synthetase (LARS2) gene represents a novel type 2 diabetes susceptibility gene. Diabetes 54, 1892-1895 (2005).
58. Jordanova, A. et al. Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nature Genet. 38, 197-202 (2006).
59. Dubourg, O. et al. The G526R glycyl-tRNA synthetase gene mutation in distal hereditary motor neuropathy type V. Neurology 66, 1721-1726 (2006).
60. Antonellis, A. et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am. J. Hum. Genet. 72, 1293-1299 (2003). The first report of a link between mutations in amino-acyl-tRNA synthetase genes and human disease.
61. Seburn, K. L., Nangle, L. A., Cox, G. A., Schimmel, P. & Burgess, R. W. An active dominant mutation of glycyl-tRNA synthetase causes neuropathy in a Charcot-Marie-Tooth 2D mouse model. Neuron 51, 715-726 (2006).
62. Lee, J. W. et al. Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature 443, 50-55 (2006).
63. Dobson, C. M. Protein folding and its links with human disease. Biochem. Soc. Symp. 68, 1-26 (2001).
64. Gatchel, J. R. & Zoghbi, H. Y. Diseases of unstable repeat expansion: mechanisms and common principles. Nature Rev. Genet. 6, 743-755 (2005).
65. Park, S. G., Ewalt, K. L. & Kim, S. Functional expansion of aminoacyl-tRNA synthetases and their interacting factors: new perspectives on housekeepers. Trends Biochem. Sci. 30, 569-574 (2005). A review describing additional roles of amino-acyl-tRNA synthetases in a wide variety of functions different from amino acylation, illustrating the additional roles of translation factors.
66. Taylor, R. W. & Turnbull, D. M. Mitochondrial DNA mutations in human disease. Nature Rev. Genet. 6, 389-402 (2005).
67. Shoubridge, E. A. & Sasarman, F. in Translational Control in Biology and Medicine (eds Mathews, M. B., Sonenberg, N. & Hershey, J. W. B.) 775-801 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2006).
68. Schapira, A. H. Mitochondrial disease. Lancet 368, 70-82 (2006).
69. Robinson, B. H. Lactic acidemia and mitochondrial disease. Mol. Genet. Metab. 89, 3-13 (2006).
70. Finsterer, J. Central nervous system manifestations of mitochondrial disorders. Acta Neurol. Scand. 114, 217-238 (2006).
71. DiMauro, S. Mitochondrial myopathies. Curr. Opin. Rheumatol. 18, 636-641 (2006).
72. Jacobs, H. T. & Turnbull, D. M. Nuclear genes and mitochondrial translation: a new class of genetic disease. Trends Genet. 21, 312-314 (2005).
73. Leu(UUR).
74. Park, H., Davidson, E. & King, M. P. The pathogenic A3243G mutation in human mitochondrial tRNALeu(UUR) decreases the efficiency of aminoacylation. Biochemistry 42, 958-964 (2003).
75. Suzuki, T., Suzuki, T., Wada, T., Saigo, K. & Watanabe, K. Taurine as a constituent of mitochondrial tRNAs: new insights into the functions of taurine and human mitochondrial diseases. EMBO J. 21, 6581-6589 (2002).
76. Borner, G. V. et al. Decreased aminoacylation of mutant tRNAs in MELAS but not in MERRF patients. Hum. Mol. Genet. 9, 467-475 (2000).
77. Shoffner, J. M. et al. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 61, 931-937 (1990).
78. Enriquez, J. A., Chomyn, A. & Attardi, G. mtDNA mutation in MERRF syndrome causes defective aminoacylation of tRNA(Lys) and premature translation termination. Nature Genet. 10, 47-55 (1995).
79. Ravn, K. et al. An mtDNA mutation, 14453G > A, in the NADH dehydrogenase subunit 6 associated with severe MELAS syndrome. Eur. J. Hum. Genet. 9, 805-809 (2001).
80. Tyr. J. Biomol. Struct. Dyn. 15, 1121-1132 (1998).
81. Bykhovskaya, Y., Casas, K., Mengesha, E., Inbal, A. & Fischel-Ghodsian, N. Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). Am. J. Hum. Genet. 74, 1303-1308 (2004).
82. Van der Knaap, M. S. et al. A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Ann. Neurol. 53, 252-258 (2003).
83. Scheper, G. C. et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nature Genet. 39, 534-539 (2007).
84. Seneca, S. et al. A mitochondrial tRNA aspartate mutation causing isolated mitochondrial myopathy. Am. J. Med. Genet. A 137, 170-175 (2005).
85. Miller, C. et al. Defective mitochondrial translation caused by a ribosomal protein (MRPS16) mutation. Ann. Neurol. 56, 734-738 (2004).
86. O'Brien, T. W., O'Brien, B. J. & Norman, R. A. Nuclear MRP genes and mitochondrial disease. Gene 354, 147-151 (2005).
87. Nolden, M. et al. The m-AAA protease defective in hereditary spastic paraplegia controls ribosome assembly in mitochondria. Cell 123, 277-289 (2005).
88. Koppen, M., Metodiev, M. D., Casari, G., Rugarli, E. I. & Langer, T. Variable and tissue-specific subunit composition of mitochondrial m-AAA protease complexes linked to hereditary spastic paraplegia. Mol. Cell. Biol. 27, 758-767 (2007).
89. Valente, L. et al. Infantile encephalopathy and defective mitochondrial DNA translation in patients with mutations of mitochondrial elongation factors EFG1 and EFTu. Am. J. Hum. Genet. 80, 44-58 (2007).
90. Smeitink, J. A. et al. Distinct clinical phenotypes associated with a mutation in the mitochondrial translation elongation factor EFTs. Am. J. Hum. Genet. 79, 869-877 (2006).
91. Coenen, M. J. et al. Mutant mitochondrial elongation factor G1 and combined oxidative phosphorylation deficiency. N. Engl. J. Med. 351, 2080-2086 (2004). This elegant study, which used complementation of the mitochondrial defect in patient fibroblasts, led to the discovery of the first nuclear-encoded translation factor known to be involved in mitochondrial disease.
92. Antonicka, H., Sasarman, F., Kennaway, N. G. & Shoubridge, E. A. The molecular basis for tissue specificity of the oxidative phosphorylation deficiencies in patients with mutations in the mitochondrial translation factor EFG1. Hum. Mol. Genet. 15, 1835-1846 (2006).
93. DiMauro, S. & Schon, E. A. Mitochondrial respiratory-chain diseases. N. Engl. J. Med. 348, 2656-2668 (2003).
94. Shoubridge, E. A. Nuclear genetic defects of oxidative phosphorylation. Hum. Mol. Genet. 10, 2277-2284 (2001).
95. Papapetropoulos, S. et al. Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson's disease. Gene Expr. 13, 205-215 (2006).
96. Grazina, M. et al. Genetic basis of Alzheimer's dementia: role of mtDNA mutations. Genes Brain Behav. 5, S92-S107 (2006).
97. Liu, C. Y., Wong, H. N., Schauerte, J. A. & Kaufman, R. J. The protein kinase/endoribonuclease IRE1α that signals the unfolded protein response has a luminal N-terminal ligand-independent dimerization domain. J. Biol. Chem. 277, 18346-18356 (2002).
98. Wek, R. C., Jiang, H. Y. & Anthony, T. G. Coping with stress: eIF2 kinases and translational control. Biochem. Soc. Trans. 34, 7-11 (2006).
99. Harding, H. P. et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol. Cell 6, 1099-1108 (2000).
100. Jeppesen, T. D. et al. Muscle phenotype and mutation load in 51 persons with the 3243A > G mitochondrial DNA mutation. Arch. Neurol. 63, 1701-1706 (2006). This study, involving 51 patients with the same mutation but a wide spectrum of clinical severity, establishes the correlation between muscle genotype and clinical phenotype in MELAS.
101. Ehrenberg, M., Hauryliuk, V., Crist, C. G. & Nakamura, Y. in Translational Control in Biology and Medicine (eds Mathews, M. B., Sonenberg, N. & Hershey, J. W. B.) 173-196 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2006).
102. Leegwater, P. A. J. et al. Subunits of the translation initiation factor eIF2B are mutated in leukoencephaly with vanishing white matter. Nature Genetics 29, 383-388 (2001).
103. Delepine, M. et al. eIF2AK3, encoding translation initiation factor 2-α kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nature Genet. 25, 406-409 (2000).
104. Inbal, A. et al. Myopathy, lactic acidosis, and sideroblastic anemia: a new syndrome. Am. J. Med. Genet. 55, 372-378 (1995).
105. Heiss, N. S. et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nature Genet. 19, 32-38 (1998).
106. Boocock, G. R. et al. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nature Genet. 33, 97-101 (2003).
107. Ridanpaa, M. et al. Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. Cell 104, 195-203 (2001).
108. Casari, G. et al. Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell 93, 973-983 (1998).
109. -/- mice reveals a role for translational control in secretory cell survival. Mol. Cell 7, 1153-1163 (2001).
110. Guo, F. & Cavener, D. R. The GCN2 eIF2α kinase regulates fatty-acid homeostasis in the liver during deprivation of an essential amino acid. Cell Metab. 5, 103-114 (2007).
111. Han, A. P. et al. Heme-regulated eIF2α kinase (HRI) is required for translational regulation and survival of erythroid precursors in iron deficiency. EMBO J. 20, 6909-6918 (2001).
112. Le Bacquer, O. et al. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J. Clin. Invest. 117, 387-396 (2007).
113. Scheuner, D. et al. Control of mRNA translation preserves endoplasmic reticulum function in β cells and maintains glucose homeostasis. Nature Med. 11, 757-764 (2005).
114. Zhang, S., Shi, M., Hui, C. C. & Rommens, J. M. Loss of the mouse ortholog of the Shwachman-Diamond syndrome gene (Sbds) results in early embryonic lethality. Mol. Cell. Biol. 26, 6656-6663 (2006).
115. Matsson, H. et al. Erythropoiesis in the Rps19 disrupted mouse: analysis of erythropoietin response and biochemical markers for Diamond-Blackfan anemia. Blood Cells Mol. Dis. 36, 259-264 (2006).
116. He, J. et al. Targeted disruption of Dkc1, the gene mutated in X-linked dyskeratosis congenita, causes embryonic lethality in mice. Oncogene 21, 7740-7744 (2002).
117. Leu(UUR) genes. Pediatrics 114, 443-450 (2004).